Free Republic

Vitals Major Finding: Eplerenone reduced the risk of cardiovascular death or heart failure hospitalization by 37%, compared with placebo. Data Source: Phase III randomized trial in 2,737 patients with NYHA class II heart failure. Disclosures: EMPHASIS-HF was funded by Pfizer. Dr. Zannad reported receiving grants from and consulting for Pfizer. Two coauthors are Pfizer employees, and several others reported Pfizer grants and consultancy. CHICAGO — Adding eplerenone to standard therapy significantly cut the risk of cardiovascular death and heart failure hospitalization by more than one-third in patients with mild heart failure in the phase III EMPHASIS-HF trial. The primary composite...